Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)

被引：75
|
作者：
Figlin, R. A.
Hutson, T. E.
Tomczak, P.
Michaelson, M. D.
Bukowski, R. M.
Negrier, S.
Huang, X.
Kim, S. T.
Chen, I.
Motzer, R. J.
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[2] Baylor Sammons Canc Ctr Texas Oncol, Dallas, TX USA
[3] Klin Onkologii Oddzial Chemioterapii, Poznan, Poland
[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[5] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[6] Ctr Leon Berard, F-69373 Lyon, France
[7] Pfizer Global Res & Dev, La Jolla, CA USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5024
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Sunitinib versus interferon-α for first-line treatment of metastatic renal cell carcinoma:: Updated results and further prognostic factor analyses
    Gruenwald, V.
    Eberhardt, W.
    Ringhoffer, M.
    Jakse, G.
    Motzer, R. J.
    ONKOLOGIE, 2008, 31 : 179 - 179
  • [42] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [43] Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC).
    Iacovelli, Roberto
    Derosa, Lisa
    Massari, Francesco
    Verri, Elena
    Galli, Luca
    Ciccarese, Chiara
    Rocca, Maria Cossu
    Cianci, Claudia
    Bimbatti, Davide
    Aurilio, Gaetano
    Antonuzzo, Andrea
    Fantinel, Emanuela
    Cullura, Daniela
    Ricci, Sergio
    Modena, Alessandra
    Falcone, Alfredo
    Tortora, Giampaolo
    Nole, Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [44] Cost-effectiveness of pazopanib (PAZ) versus sunitinib (SUN) as first-line treatment of metastatic renal cell carcinoma (mRCC) patients in the United States
    Nakhaipour, Hamid Reza
    Dales, Tom
    Amdahl, Jordan
    Diaz, Jose
    Hackshaw, Michelle Denise
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Remak, Edit
    Charbonneau, Claudie
    Negrier, Sylvie
    Kim, Sindy T.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
  • [46] ECONOMIC EVALUATION OF SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Prieto, V. A.
    Reyes, J. M.
    Lopez-Cabra, C.
    Diaz, J. A.
    Urrego-Novoa, J. R.
    VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [47] Economic evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma in Mexico
    Emilio, Mucino-Ortega
    Joaquin Federico, Mould-Quevedo
    GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (02): : 48 - 57
  • [48] Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.
    Park, Seongjoon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongchel
    Ahn, Jin-Hee
    Lee, Dae Ho
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan
    Al-Rabayah, Abeer A.
    Sawalha, Razan
    Al Froukh, Rawan Fawzi
    Al-Bawab, Rand
    Jaddoua, Saad M.
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2021, 12 (04) : 566 - 573
  • [50] COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VERSUS SORAFENIB AND BEVACIZUMAB plus INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN ECUADOR
    Torres Toala, F. G.
    Albuja Riofrio, M. F.
    Mould, J. F.
    Estevez, C.
    VALUE IN HEALTH, 2013, 16 (03) : A139 - A139
12345